Counting chickens

A growing sense has emerged that events in Washington are working in biotech's favor, but not without warnings from political pros that the final shape or fate of health care reform cannot yet be predicted safely.

A quick tour of the Capital last week would have demonstated how easy it is to go full circle between confidence and anxiety and back again.

Confidence is rising in some parts of Wall Street
and in Washington that the Health Care Task Force's plan will not include price controls on new drugs, the major issue for biotech companies.